Sexual intimacy is an important part of a couples’ relationship. On June 21, 2019, the FDA approved a new novel medication for hypoactive sexual desire disorder in women. The medication, Vylessi, is a melanocortin receptor activator, which is different then the previously approved medication for the same condition, Addyi. In this episode, we will review the MOA and data behind this new medication.